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The discovery of HIV in 1983 originated from a collec-
tive adventure, which mobilized clinicians, researchers
and patients altogether. This collaboration was crucial
to rapidly expand the knowledge of the virus and
develop the first diagnostic tests and antiretroviral ther-
apy (ART).
More than 25 years after the discovery of the etiologi-
cal agent responsible for AIDS, research priorities still
remain care, treatment and prevention with the major
objective of developing a preventive vaccine.
Today, we have gained significant insight into the
virus pathogenesis. The evolution and progression of the
disease caused by HIV is closely linked to a number of
determinants of the virus itself and the host. We also
know today that, very early after exposure to the virus, a
massive depletion of CCR5+ CD4+ T memory cells
associated with microbial translocation occurs in the
gastrointestinal tract of HIV infected patients. HIV
infection is clearly inducing an inflammation and a gen-
eralized and persistent T cell activation, which may play
a role in the persistence of HIV infection, resulting from
the establishment of permanent reservoirs into host
cells and in different host compartments. The reduction
of the size of these reservoirs is representing one of the
main challenges for the development of future therapeu-
tic strategies.
Among other challenges in therapy, we also need to
better understand the mechanisms leading to the severe
complications (cardiovascular diseases, accelerated
aging, cancer...) observed in some patients on long-term
ART. Again, whether the inflammatory response is con-
tributing or not to these complications remains an
opened question.
The early acute phase of HIV infection appears there-
fore to be crucial in determining disease progression.
Given the importance of the innate immune responses
in this very early phase following infection and in driv-
ing adaptive immunity, further research on innate
immunity in HIV infection are certainly among priori-
ties for elaborating future therapeutic and vaccine
strategies.
New technologies are today available to address all
these scientific challenges. But they will only be over-
come with a multidisciplinary and translational research
for the global benefit of humanity.
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